Colorectal Cancer Clinical Trials in Pennsylvania

Showing 141-160 of 326 trials

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

NCT05039177

* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.

Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma

Erasca, Inc.102 participantsStarted Sep 2021

Birmingham, Alabama, United States • Duarte, California, United States • Orange, California, United States +11 more locations

TERMINATEDPhase 195 miles

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

NCT05824559

This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Colorectal Cancer

MEI Pharma, Inc.23 participantsStarted Aug 2023

Los Angeles, California, United States • Miami Beach, Florida, United States • Baltimore, Maryland, United States +4 more locations

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Colorectal Cancer Trials in Other Cities

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

COLOR II: Laparoscopic Versus Open Rectal Cancer Removal

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Other Conditions in Pennsylvania